Yong Huang

Yong Huang

Auto-generated profile, based on publicly available information

Yong Huang

Huidu Medical Sciences, Shanghai, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in European Urology
Verified
Journal Article
Closed access
HFHeidi Fettke
Heidi Fettke
EKEdmond M. Kwan
Edmond M. Kwan
MDMaria M. Docanto
Maria M. Docanto
PBPatricia Bukczynska
Patricia Bukczynska
NNNicole Ng
Nicole Ng
AAArun A. Azad
Arun A. Azad

18 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PZPeng Zhang
Peng Zhang
SYShuhong Yi
Shuhong Yi
XLXi Li
Xi Li
RLRuilei Liu
Ruilei Liu
HJHua Jiang
Hua Jiang
YHYong Huang
Yong Huang
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) in human immune system. DC-based tumor vaccine has met with some success in specific malignancies, inclusive of breast cancer. In this study, we electrofused MDA-MB-231 breast cancer cell line with day-3 DCs derived from peripheral blood monocytes, and explored the biological characteristics of fusion vaccine and its anti-tumor effects in vitro. Day-3 mature DCs were generated from day-2 immature DCs by adding cocktails composed of TNF-α, IL-1β, IL-6 and PEG2. Day-3 mature DCs were identified and electofused with breast cancer cells to generate fusion vaccine. Phenotype of fusion cells were identified by fluorescence microscope and flow cytometer. The fusion vaccine was evaluated for T cell proliferation, secretion of IL-12 and IFN-γ, and induction of tumor-specific CTL response. Despite differences in morphology, day-3 and day-7 DC expressed similar surface markers. The secretion of IL-12 and IFN-γ in fusion vaccine group was much higher than that in the control group. Compared with control group, DC-tumor fusion vaccine could better stimulate the proliferation of allogeneic T lymphocytes and kill more breast cancer cells (MDA-MB-231) in vitro. Day-3 DCs had the same function as the day-7 DCs, but with a shorter culture period. Our findings suggested that day-3 DCs fused with whole apoptotic breast cancer cells could elicit effective specific antitumor T cell responses in vitro and may be developed into a prospective candidate for adoptivet immunotherapy.

1 November 2015 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
HBHelen MBChB Byakwaga
Helen MBChB Byakwaga
PHPeter W. Hunt
Peter W. Hunt
MLMiriam MBChB Laker-Oketta
Miriam MBChB Laker-Oketta
DGDavid V. Glidden
David V. Glidden
YHYong Huang
Yong Huang
JMJeffrey N. Martin
Jeffrey N. Martin
Background: Other than Kaposi sarcoma (KS)–associated herpesvirus and CD4+ T-cell lymphopenia, the mechanisms responsible for KS in the context of HIV are poorly understood. One recently explored pathway of HIV pathogenesis involves induction of the enzyme indoleamine 2,3-dioxygenase-1 (IDO), which catabolizes tryptophan into kynurenine and several other immunologically active metabolites that suppress T-cell proliferation. We investigated the role of IDO in the development of KS in HIV disease. Methods: In a case–control study among untreated HIV-infected Ugandans, cases were adults with KS and controls were without KS. IDO activity was assessed by the ratio of plasma kynurenine to tryptophan levels (KT ratio), measured by liquid chromatography–tandem mass spectrometry. Results: We studied 631 HIV-infected subjects: 222 KS cases and 409 controls. Non-KS controls had a higher median plasma KT ratio (130, interquartile range: 90 to 190 nM/μM) than KS cases (110, interquartile range: 90 to 150 nM/μM) (P = 0.004). After adjustment for age, sex, CD4 count, and plasma HIV RNA level, subjects with the highest (fourth quartile) plasma KT ratios had a 59% reduction (95% confidence interval: 27% to 77%) in the odds of KS compared with those with the lowest (first quartile) levels. KS was also independently associated with lower CD4+ count, higher plasma HIV RNA, and men. Conclusions: Among HIV-infected individuals, greater activity of the kynurenine pathway of tryptophan catabolism, as evidenced by higher levels of plasma KT ratio, was associated with lower occurrence of KS. Some consequences of immune activation in HIV infection might actually suppress certain cancers.

5 June 2020 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
YHYong Huang
Yong Huang
KGKuanxue Ge
Kuanxue Ge
GFGuangshun Fu
Guangshun Fu
JCJunfeng Chu
Junfeng Chu
WWWei Wei
Wei Wei
Background: It was a difficult question to identify candidates who would benefit most from adjuvant chemotherapy in stage II colon cancer because of the paucity of relevant conclusive clinical trial results. We aimed to assess if mucinous adenocarcinoma (MUA) could be an indicator for the efficacy of adjuvant chemotherapy in stage II colon cancer. Methods:Using SEER*Stat software V.8.3.5, eligible patients were then recruited from the SEER database. A χ2 test was applied to compare the distribution of different categorical variables between nonmucinous adenocarcinoma (NMUA) and MUA groups. We then used the Kaplan–Meier method to analyze overall survival (OS) of different histological types in stage II colon cancer, and the log-rank test was then used to assess the OS differences. The Cox proportional regression risk models were also built in our analyses to eliminate potential crossed bias from other prognostic factors. Results:A total of 50,065 patients diagnosed with stage II colon cancer were recruited from the SEER database from 2004 to 2011; all the patients were divided into two groups, including NMUA (n = 44,785) and MUA (n = 5,280). The Cox analysis of the histological type indicated that the survival difference between MUA and NMUA failed to reach statistical significance in stage II colon cancer (P = 0.360). In NMUA, patients treated with adjuvant chemotherapy were independently associated with 37.2% decreased risk of overall mortality compared with those not [hazard ratio (HR) = 0.628, 95% confidence interval (CI) = 0.601-1.656, P < 0.001]; in MUA, the number increased to 41.5% (HR = 0.585, 95% CI = 0.515-0.665, P < 0.001). Conclusions:Our study showed that the survival difference between MUA and NMUA failed to reach statistical significance in stage II colon cancer. More importantly, our study had provided the first evidence that chemotherapy would offer higher survival improvement in MUA compared with NMUA in stage II colon cancer; mucinous histology might be an indicator for enhanced survival benefit of chemotherapy in stage II colon cancer.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YHYong Huang
Yong Huang
MLMeijun Long
Meijun Long
JAJun An
Jun An
MTMi Tang
Mi Tang
RLRenbin Liu
Renbin Liu
e12566 Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited effective treatment options. New therapeutic approaches are urgently needed to improve the prognosis of TNBC. We studied the character of Runx2 gene in breast cancer and whether the Runx2-dendritic cell (DC) vaccine can induce specific antitumor effect on triple negative breast cancer in vitro. Methods: The expression of Runx2 in triple negative breast cancer,non-triple negative breast cancer and normal breast cells were analyzed by RT-PCR,immunocytochemistry and westernblot. DC were isolated and cultured from peripheral blood of healthy donors, the surface maker CD11c, CD80, CD86 and HLA-DR were analyzed with flow cytometry. Runx2 lentivirus were prepared to infect DC and divided in transfected group, negative group and blank group. Fluorescence microscope, PCR and Westernblot tested its transfection efficiency of all groups. DC and T cells were cultured together to induce CTL, ELISA was used to detect the secretion of IL-12 and IFN-γ. The killing ability of CTL were calculated by MTT. Results: PCR results shown the ΔCT value of Runx2 in MDA –MB -231,MCF7 and MCF10A were 10.37±0.61, 11.86±0.59, 12.97±0.06(P < 0.05)respectively. Both immunocytochemistry and westernblot showed Runx2 were strongly positive in MDA –MB -231, but weaker in MCF7 and MCF10A.In this study, Runx2-lentivirus were prepared and transfected DC. Rich green flurescent confirmed that the Runx2 gene were successfully turned into mature DC .Then the transfected DC were co-cultured with T cells, and the secretion of IL-12、IFN-γ(pg/ml)were measured as 170.33±5.03、517.15±5.88. While the secretion of IL-12、IFN-γ were 72.30±3.05、171.57±1.37(P < 0.05)in non-transfected group. And the killing ratio of cytotoxic T cells of transfected group on triple negative breast cancer was 60.02±3.51 compared with 25.57±3.64(P < 0.05)of the control group. Conclusions: Runx2 maybe a new target for triple negative breast cancer treatment. Runx2 can transduce DC successfully and the vaccine induce specific CTL and strong cytotoxicity against triple negative breast cancer.